Evidence map›Paper›PMID 42611163›Full record

ArticleAmerican journal of clinical dermatology2026

Efficacy and Safety of SSGJ-608 in Moderate-to-Severe Plaque Psoriasis: A Pivotal Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial.

Ling Han, Haihong Qin, Xiaonian Lu, Litao Zhang, Linfeng Li, Hongfang Han, Jinyan Wang, Xinsuo Duan, Dongjie Sun, Wenlin Yang and 34 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05536726 (A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Patients With Moderate-to-Severe Plaque Psoriasis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05536726 phase3completednot on this map

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Patients With Moderate-to-Severe Plaque Psoriasis

TypeinterventionalSponsorSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Ran2023 to 2024Enrolled458ConditionsPsoriasisArms608 Q2W, 608 Q4W, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors.

Ling Han *Huashan Hospital, Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China.
Haihong Qin *Huashan Hospital, Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China.
Xiaonian Lu *Huashan Hospital, Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China.
Litao ZhangAffiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin, China.
Linfeng LiBeijing Friendship Hospital, Capital Medical University, Beijing, China.
Hongfang HanThe First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Jinyan WangNingbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China.
Xinsuo DuanAffiliated Hospital of Chengde Medical University, Chengde, Hebei, China.
Dongjie SunThe First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Wenlin YangThe Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Hong RenLianyungang First People's Hospital, Lianyungang, Jiangsu, China.
Xiaohua WangDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Chao CiYijishan Hospital of Wannan Medical College, Wuhu, Anhui, China.
Yu WangAffiliated Hospital of Guizhou Medical University, Guizhou, Guiyang, China.
Xiuping HanShengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Wenhao YinThe First Hospital of Jiaxing, Jiaxing, Zhejiang, China.
Chunshui YuSuining Central Hospital, Suining, Sichuan, China.
Min ZhangInner Mongolia Baogang Hospital, Baotou, Inner Mongolia Autonomous Region, China.
Jianjian ZhuChangde First People's Hospital, Changde, Hunan, China.
Liming WuHangzhou First People's Hospital, Hangzhou, Zhejiang, China.
Zudong MengShiyan People's Hospital, Shiyan, Hubei, China.
Tongxiang ZengJingzhou Central Hospital, Jingzhou, Hubei, China.
Huiping WangTianjin Medical University General Hospital, Tianjin, China.
Yunyun ShanHangzhou Third People's Hospital, Hangzhou, Zhejiang, China.
Yangfeng DingShanghai Dermatology Hospital, Shanghai, China.
Wenli FengThe Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Xiaoli ZhangWuxi Second People's Hospital, Wuxi, Jiangsu, China.
Guoqiang ZhangThe First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Qing GuoSun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Hao ChengSir Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Chao JiThe First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Ruihua FangGuangzhou First People's Hospital, Guangzhou, Guangdong, China.
Xiuqin DongGuangdong Provincial People's Hospital, Guangzhou, Guangdong, China.
Xiaofang ZhuNorthern Jiangsu People's Hospital, Yangzhou, Jiangsu, China.
Tiechi LeiRenmin Hospital of Wuhan University, Wuhan, Hubei, China.
Xueyuan YangHospital for Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
Rong XiaoThe Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Zhijun LiuThe First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Xiaohua TaoZhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Rixin ChenNanyang First People's Hospital, Nanyang, Henan, China.
Jing LouSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China.
Yanli LiuSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China.
Jing ZhangHuashan Hospital, Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China. zhangj_fudan@163.com.
Jinhua XuHuashan Hospital, Fudan University, No. 12 Middle Wulumuqi Road, Shanghai, 200040, China. xjhhsyy@163.com.ORCID http://orcid.org/0000-0001-9104-1294

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSSGJ-608 is a recombinant, humanized, immunoglobulin G1 monoclonal antibody that targets human interleukin-17A with high specificity and high affinity.

objectiveWe aimed to evaluate the efficacy and safety of SSGJ-608 in patients with moderate-to-severe psoriasis in China.

methodsAdult patients aged 18 years or older with moderate-to-severe plaque psoriasis were randomly assigned (2:2:1) to receive subcutaneous injections of placebo (placebo group), 80 mg of SSGJ-608 every 2 weeks after a starting dose of 160 mg at week 0 (608A group), or 160 mg of SSGJ-608 every 4 weeks (608B group). At week 12, patients in the 608A group received SSGJ-608 80 mg every 4 weeks, patients in the 608B group received SSGJ-608 160 mg every 8 weeks, and patients in the placebo group were re-allocated (1:1) to either the 608A or 608B group to receive 608 80 mg every 4 weeks (with an additional 160-mg loading dose of SSGJ-608 at week 12) or 160 mg every 8 weeks. All patients received treatment until week 48. The primary endpoints were a ≥75% improvement from baseline in the Psoriasis Area and Severity Index score (PASI75) and a static Physicians Global Assessment score of 0/1 (sPGA 0/1) at week 12.

resultsA total of 458 patients were randomly assigned to either the 608A group (n = 184), the 608B group (n = 183), or the placebo group (n = 91). At week 12, compared with those in the placebo group, a greater proportion of patients in the 608A group and in the 608B group achieved the primary endpoints of PASI75 (95.1% vs 93.4% vs 8.8%) and sPGA of 0 or 1 (76.1% vs 67.2% vs 1.1%). At week 52, PASI75 was maintained by 93.7% in the 608A group and 93.6% in the 608B group, sPGA of 0 or 1 was maintained by 89.3% in the 608A group and 89.4% in the 608B group, PASI90 was maintained by 92.6% in the 608A group and 92.5% in the 608B group, respectively. Both treatment groups demonstrated a favorable safety profile, with no increase in risk observed with longer drug exposure.

conclusionsSSGJ-608 showed rapid and robust clinical response at week 12 and through week 52, and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis. CLINICAL

trial registrationClinicalTrials.gov Identifiers: NCT05536726.

Identifiers

PMID42611163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.